DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 76 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Divis Labs Share Price Live Updates: Divis Labs Stock Details

Economic Times 3 hrs ago·22 Sept 2026, 2:40 am

Divis Laboratories, a leading pharmaceutical company, is currently in the news as investors closely monitor its stock price movements. The company is known for its strong presence in the active pharmaceutical ingredients (API) market, which has made it a key player in the global healthcare supply chain.

For investors, the focus is on how market sentiment and broader industry trends are influencing the stock's valuation. As a large-cap entity, its performance often reflects the health of the broader pharmaceutical sector and investor confidence in India's manufacturing capabilities.

Moving forward, market participants will be watching for updates on production volumes, export demand, and any regulatory or operational changes that could impact the company's financial outlook.